John Mendlein
Director at Fate Therapeutics Inc (FATE)
John Mendlein has filed 13 insider reports with the SEC since June 2021, as director at Fate Therapeutics Inc (FATE) and director at Omega Therapeutics, Inc. (OMGA). John Mendlein made no open-market purchases or sales in the last 12 months. The latest filing, on December 29, 2025, is a Form 144 notice: John Mendlein plans to sell 38,428 FATE shares (~$38.9K).
- Filings
- 13
- Companies
- 2
- Bought on market
- $698K
- Sold on market
- $1.14M
Companies where John Mendlein is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 311,231 | $698K | $1.14M | $5.60 | $0.919-84% | Dec 29, 2025 | |
| Director | Jun 21, 2024 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Dec 29, 2025~$38.9KFATEJohn Mendlein plans to sell 38,428 shares (~$38.9K)Form 144Planned sale
- May 29, 2025FATESEC Form 4 filed by Director Mendlein JohnForm 4Grant or award
- Jun 20, 2024OMGASEC Form 4 filed by Director Mendlein JohnForm 4Grant or award
- Jun 7, 2024FATESEC Form 4 filed by Director Mendlein JohnForm 4Grant or award
- Jun 7, 2023OMGASEC Form 4 filed by Mendlein JohnForm 4Grant or award
- Jun 6, 2023FATESEC Form 4 filed by Mendlein JohnForm 4Grant or award
- Jan 19, 2023FATESEC Form 4: Mendlein John exercised 28,461 shares at a strike of $1.37, increasing direct ownership by 10% to 311,231 unitsForm 4Exercise or conversion of a derivative
- Jan 13, 2023+$698KFATESEC Form 4: Mendlein John bought $698,138 worth of shares (124,679 units at $5.60), increasing direct ownership by 79% to 282,770 unitsForm 4Open-market purchase
- Jun 9, 2022FATESEC Form 4: Mendlein John was granted 8,650 shares, increasing direct ownership by 5% to 166,741 unitsForm 4Grant or award
- Jun 8, 2022OMGASEC Form 4 filed by Mendlein JohnForm 4Grant or award
- Jun 3, 2022-$31.1KFATESEC Form 4: Mendlein John sold $31,086 worth of shares (1,364 units at $22.79), decreasing direct ownership by 0.86% to 158,091 units to cover taxesForm 4Open-market sale
- Mar 10, 2022-$1.11MFATESEC Form 4: Mendlein John exercised 31,562 shares at a strike of $1.63 and sold $1,105,200 worth of shares (31,562 units at $35.02) as part of a pre-agreed trading planForm 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Jun 2, 2021FATESEC Form 4: MENDLEIN JOHN was granted 2,681 units of Common Stock, increasing direct ownership by 2% to 159,455 unitsForm 4Grant or award
Compare John Mendlein with
- John Mendlein vs Kamal Adawi1 shared
- John Mendlein vs Cindy Tahl1 shared
- John Mendlein vs Bahram Valamehr1 shared
- John Mendlein vs Michael Stewart Lee1 shared
- John Mendlein vs Yuan Xu1 shared
- John Mendlein vs Karin Jooss1 shared
Other insiders at the same companies
- Kamal AdawiFATE
- Cindy TahlFATE
- Bahram ValamehrFATE
- Redmile Group, LLCFATE
- Michael Stewart LeeFATE
- Yuan XuFATE
- Karin JoossFATE
- Robert S EpsteinFATE
- Shefali AgarwalFATE
- Matt AbernethyFATE
- William H RastetterFATE
- Laura HamillFATE
- RedCo II Master Fund, L.P.FATE
- Neelufar MozaffarianFATE
- Richard A YoungOMGA
- Jeffrey T VarsaloneOMGA
Questions about John Mendlein
- What is John Mendlein's role at Fate Therapeutics Inc?
- John Mendlein reports to the SEC as director at Fate Therapeutics Inc (FATE), according to the latest filing on December 29, 2025. John Mendlein has also filed as director at Omega Therapeutics, Inc. (OMGA).
- How many shares does John Mendlein own?
- After the latest filing that states it, John Mendlein directly owned 311,231 shares of Fate Therapeutics Inc (FATE). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has John Mendlein bought or sold stock recently?
- The most recent open-market purchase was on January 13, 2023: bought 124,679 shares of Fate Therapeutics Inc (FATE) for $698K at an average of $5.60. The most recent open-market sale was on June 3, 2022: sold 1,364 shares of Fate Therapeutics Inc (FATE) for $31.1K at an average of $22.79.
- How do I get alerts when John Mendlein files?
- Follow John Mendlein on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by John Mendlein (SEC CIK 0001238362). Totals count each trade once, skipping amendments whose original is on file, from Jun 4, 2021 on. View on SEC EDGAR · Get this as JSON